A fixed-dose combination antacid, antiflatulent, and local anesthetic used for rapid symptomatic relief in acid-peptic disorders. Magaldrate is a hydroxymagnesium aluminate complex providing rapid and sustained neutralization of gastric acid. Simethicone is an antifoaming agent that reduces gas and bloating. Oxetacaine is a potent surface anesthetic that provides immediate relief from pain and burning sensations by numbing the gastric mucosa.
Adult: 1-2 tablets or 5-10 ml of suspension, to be chewed or taken orally, 3-4 times a day, preferably 20-60 minutes after meals and at bedtime, or as directed by the physician. Maximum: 8 doses per day.
Note: Tablets: Chew thoroughly before swallowing. Do not swallow whole. Follow with a half glass of water if needed. Suspension: Shake well before use. Measure dose accurately with provided measuring cup/spoon. Take 20-60 minutes after meals and at bedtime for best results. Maintain at least a 2-hour gap between this medication and other oral drugs (especially antibiotics like tetracyclines, fluoroquinolones; antifungals like ketoconazole; iron supplements; bisphosphonates; levothyroxine) to avoid absorption interference.
Magaldrate: A co-precipitate of aluminum and magnesium hydroxides that reacts rapidly with gastric hydrochloric acid to raise the pH, providing both immediate and sustained buffering action. It also adsorbs pepsin and bile salts. Simethicone: A silicone polymer that reduces the surface tension of gas bubbles in the GI tract, causing them to coalesce and be more easily expelled via belching or passing flatus. Oxetacaine: A potent surface anesthetic of the ester type that stabilizes neuronal membranes by inhibiting sodium ion influx, blocking the initiation and conduction of nerve impulses, thereby numbing the gastric and esophageal mucosa to provide immediate pain relief.
Pregnancy: Category C (US FDA). Animal reproduction studies have not been conducted. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Short-term, intermittent use for symptom relief is generally considered acceptable, but should be under medical supervision. Avoid high doses and prolonged use.
Driving: Unlikely to affect driving ability as systemic effects are minimal. However, if rare side effects like dizziness or drowsiness occur, patients should avoid driving or operating machinery.
| Tetracyclines (Doxycycline, Minocycline) | Decreased absorption of tetracycline due to chelation by aluminum/magnesium ions. | Major |
| Fluoroquinolones (Ciprofloxacin, Levofloxacin) | Markedly reduced absorption due to chelation. | Major |
| Iron Supplements (Ferrous sulfate) | Decreased iron absorption. | Moderate |
| Bisphosphonates (Alendronate, Risedronate) | Severely reduced absorption. Must be taken at a different time of day. | Major |
| Levothyroxine | Decreased absorption of levothyroxine. | Moderate |
| Digoxin | Possible decreased digoxin absorption. Monitor levels. | Moderate |
| Ketoconazole, Itraconazole | Reduced absorption due to increased gastric pH. | Major |
| H2 Blockers (Ranitidine, Famotidine) or PPIs (Omeprazole, Pantoprazole) | Pharmacodynamic interaction. Concomitant use is generally not recommended as it may reduce PPI absorption. Administer PPIs 30-60 mins before this combination. | Moderate |
| Enteric-coated tablets | May cause premature dissolution of the coating in the stomach. | Moderate |
| Anticholinergics (e.g., Dicyclomine) | Increased risk of constipation. | Minor |
Same composition (Magaldrate (540mg) + Simethicone (50mg) + Oxetacaine (10mg)), different brands: